Numerous clinical trials have demonstrated survival improvements with the addition of chemotherapy to definitive radiation therapy (RT) for head and neck cancers, as highlighted by the MACH-NC meta-analysis [1] . One important result of this study, however, was a decreasing benefit to chemotherapy with increasing age, which was independent of other covariates analyzed. Moreover, nearly 40% of deaths in patients ≥71 years of age therein were not cancer-related. Although the meta-analysis did not evaluate toxicities, numerous studies have illustrated decreased tolerance of oncologic therapies by older patients [2] [3] [4] .
Introduction demonstrated an overall survival (OS) benefit of 6% at 5 years with the addition of chemotherapy to RT [6] . However, that analysis notably underrepresented older patients, likely related to the median age of NPC patients being approximately 55 years (in the United States) [7] . Just 13% of the total MAC-NPC cohort was ≥60 years of age; although the proportion ≥70 years old was not reported, it is likely less than half of that figure.
As a result, optimal management for older (defined as ≥70 years old herein) NPC patients with respect to the additional chemotherapy is currently not well defined. Although challenging to assess with single-or multiinstitutional analyses owing to the relative rarity of older NPC patients, the National Cancer Data Base (NCDB) provides a unique resource with which to address this novel but clinically important issue. In this investigation, the largest such study to date, we evaluated national practice patterns and outcomes in older NPC patients treated with CRT versus RT alone.
Materials & Methods
The NCDB is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society, which consists of de-identified information regarding tumor characteristics, patient demographics, and patient survival for approximately 70% of the United States population [8] [9] [10] [11] [12] [13] [14] [15] . All pertinent cases are reported regularly from CoC-accredited centers and compiled into a unified dataset, which is then validated. The NCDB contains information not included in the Surveillance, Epidemiology, and End Results database, including details regarding use of systemic therapy. The data used in the study were derived from a de-identified NCDB file (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . The American College of Surgeons and the CoC have not verified and are neither responsible for the analytic or statistical methodology employed nor the conclusions drawn from these data by the investigators. As all patient information in the NCDB database is de-identified, this study was exempt from institutional review board evaluation.
Inclusion criteria for this study were patients ≥70 years of age with newly-diagnosed nasopharyngeal cancer treated with RT for curative intent. The 70-year-old threshold was utilized because it is among the most commonly used cutoff to denote "older" patients in head/neck cancer as well as many other areas of oncology [16] ; it is also close to the threshold utilized in the MACH-NC study [1] . T1N0 and M1 cases were excluded because CRT is not the consensus-based recognized treatment for these subsets; patients receiving any form of pharyngectomy were similarly removed because it is nonstandard for NPC and to isolate the effect of adding chemotherapy to RT [5] . Other exclusion criteria were incomplete staging information, palliative care treatment, and unknown information on RT and/or chemotherapy. In accordance with the variables in NCDB files, information collected on each patient broadly included demographic, clinical, and treatment data.
All statistical tests were performed with SPSS software (IBM Corporation, Armonk, NY); tests were two-sided, with a threshold of P < 0.05 for statistical significance. Univariable and multivariable logistic regression were used to determine characteristics associated with receipt of CRT. All initially examined variables were considered for inclusion into models for stepwise selection. Survival analysis (performed using Kaplan-Meier methodology) evaluated OS, defined as the interval between the date of diagnosis and the date of death or censored at last contact. Univariate and multivariate Cox proportional hazards modeling was utilized to evaluate predictors of OS.
Results
A complete flow diagram of patient selection is provided in Figure 1 . In total, 930 patients met study analysis criteria. Table 1 displays notable clinical characteristics of the analyzed patients, most (74%) of whom were 70-79 years of age. A total of 713 (77%) patients underwent CRT, whereas 217 (23%) received RT alone. After univariable analysis was performed to assess factors associated with receipt of CRT, multivariable assessment revealed that factors independently associated with decreased likelihood of CRT delivery were advancing age (P = 0.001), female gender (P = 0.014), and node-negative disease (P = 0.002). There was also a trend toward increasing CRT receipt in more recent years (2009-2013, P = 0.063).
Median follow-up was 23 months (range, 0-129 months). Kaplan-Meier estimates comparing OS in patients that received RT alone versus CRT are illustrated in Figure 2 ; median OS in the respective cohorts were 20.0 (95% confidence interval (CI), 12.8-27.3) months and 35.3 (95% CI, 29.3-41.2) months (P = 0.002).
In the overall cohort, there were several predictors of OS on univariate analysis (Table 2) . After multivariate adjustment for potential confounding factors (Table 2) , factors independently associated with poorer OS included advancing age, comorbidity index, lower income, Medicare insurance (relative to private), poor/undifferentiated/anaplastic disease, and stage IV (M0) disease (P < 0.05 for all). Of note, receipt of CRT relative to RT alone independently predicted for improved OS (hazard ratio, 0.721, 95% CI, 0.532-0.979, P = 0.036).
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Discussion
To the best of our knowledge, this is the largest report assessing practice patterns and outcomes of RT with or without chemotherapy for elderly NPC patients. Our study of a large national database of this relatively uncommon clinical circumstance notably demonstrates that the addition of chemotherapy to RT is independently associated with greater survival in older patients, indicating that the benefit of chemotherapy in NPC may extend potentially to all ages.
A main message from our analysis is that causation is not implied; it could very well be that patients receiving RT alone were not healthy enough to receive additional chemotherapy, and hence they would naturally do worse and be at greater risk of dying from noncancer causes as mentioned above. Although the lack of endpoints such as cancer-specific survival and local/regional control in the NCDB hampers firm conclusions, there are several reasons to believe this bias may be relatively minimal. First, cohorts were relatively balanced, including no differences in Charlson-Deyo comorbidity index (although this does not equate to performance status, it did independently predict for OS on Cox multivariate analysis herein). In fact, because groups were overall quite balanced, 
there was relatively little indication for propensity matching, which would have prohibitively eliminated sample size from an already limited patient population. Furthermore, there were only three variables significantly different between groups on multivariable logistic regression analysis (age, gender, and nodal status); of those three variables, the CRT cohort was younger but had a higher proportion of node-positive disease and males. Younger age has been shown to associate with more advanced disease [17] ; node-positivity and male gender also correlate with poorer prognosis [18] [19] [20] . In this manner, consistent with other work, it is plausible that chemotherapy potentially may have been given to a "higher-risk" population, and that there may be "true" benefits to adding chemotherapy [21, 22] .
Despite the large dataset offered by the NCDB, one of its major limitations is a lack of toxicity assessment. To this extent, smaller retrospective reports of older NPC patients (which have employed varying definitions of "older/elderly") suggest that despite the increase in acute toxicities when adding chemotherapy to RT, these may not be worse in severity from those experienced by younger patients [23, 24] . This is consistent with multiple studies in other head/neck neoplasms showing similar toxicities and/or outcomes in elderly patients as compared to their younger counterparts [2, [25] [26] [27] . Thus, we encourage judicious and individualized judgment when evaluating administration of CRT in elderly NPC patients; there will likely never be a "definitive answer" regarding aggressive therapies (vs. lack thereof) in elderly patients, owing to retrospective patient selection biases and varying definitions of "older/elderly" patients from study to study.
We, therefore, propose that the term "older/elderly" should not be singularly defined by age, because these patients are intrinsically heterogeneous [28] . Rather, utilization of many available measures to measure functionality (e.g., the Comprehensive Geriatric Assessment) and CRT versus RT Alone for NPC in the Elderly V. Verma et al. performance status (PS) is a more reliable way to divide "older/elderly" patients into the "functionally older/elderly" or "functionally young" [29] . For instance, Liu and colleagues did not find a benefit to adding chemotherapy to RT in NPC patients with high comorbidity indices [23] . This study was underpowered to confirm those findings. Nevertheless, these and other parameters are critically important in adequately selecting "elderly" patients that are "fit" to receive aggressive oncologic therapies.
Lastly, although one method to reduce toxicities of CRT is delivering chemotherapy and RT sequentially, we were unable to separately ascertain the benefit of concurrent versus sequential CRT. In our dataset, a large majority (77%) of CRT patients received chemotherapy and RT within 2 weeks of each other (two weeks being a previously utilized cutoff point for concurrent therapy in prior such publications [30] ). Of the remaining 23% of the CRT cohort, timing of therapies was unknown in 7%, indicating that just 16% certainly received sequential CRT. This was much too small of a sample size to analyze separately in this study. Hence, induction chemotherapy followed by RT remains an attractive option in well-selected "older" NPC patients at higher risk of toxicities. Additionally, although the use of induction chemotherapy V. Verma et al. CRT versus RT Alone for NPC in the Elderly followed by CRT could emerge as a new standard of care [31] , the phase III trial deliberately excluded patients ≥60 years of age owing to toxicity risks. However, retrospective data of patients ≥60 years treated with CRT with or without induction chemotherapy showed no outcome differences, with higher toxicities in those receiving induction therapy [32] .
Although the NCDB provides a unique platform for studying this important clinical question, this investigation still has limitations. First, NCDB studies are inherently retrospective, with selection biases and lack of several endpoints as mentioned above. Second, NCDB does not keep track of precise chemotherapy details, including specific chemotherapeutic agents, reasons for withholding chemotherapy in RT alone patients (ie. related to tolerability vs. disease-related factors), or the number of cycles of chemotherapy received. Third, the NCDB does not allow for an assessment of subsequent lines of treatment (e.g., re-irradiation, further systemic and/or targeted therapy), which could influence OS. Furthermore, the NCDB also does not provide details such as performance/functional status, Epstein-Barr virus status, or radiotherapy field design/volumes/techniques. Fourth, a major limitation of this study was too few patients for a statistically reliable subset analysis of whether benefit to CRT is limited to those with advanced versus limited nodal disease. The NCDB is also unique to the United States and thus may not be representative to other areas of the world where NPC is endemic.
Conclusions
This is the largest study to date evaluating the utility of CRT, as compared to RT alone, for older (≥70 years old) patients with NPC. Administration of CRT was independently associated with improved survival, but causation is not implied, and careful patient selection is necessary to balance treatment-related toxicity risks with potential oncologic benefits.
